Skin necrosis revealing antiphospholipid syndrome during immunotherapy for melanoma.
Gressier
Ludivine
L
Guilpain
Philippe
P
Gorin
Isabelle
I
Carlotti
Agnès
A
Goulvestre
Claire
C
Boitier
Françoise
F
Guillevin
Loïc
L
Avril
Marie-Françoise
MF
Mouthon
Luc
L
Dupin
Nicolas
N
D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D016736:Antiphospholipid Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D001706:Biopsy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D004359:Drug Therapy, Combination; D006225:Hand; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D009336:Necrosis; D011092:Polyethylene Glycols / Q000009:adverse effects; D011994:Recombinant Proteins; D012867:Skin / Q000276:immunology* / Q000473:pathology; D014034:Toes; D016896:Treatment Outcome
D000925:Anticoagulants; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b